Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria
Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol 2005;58:840-6.
Food and Drug Administration, Center for Drug Evaluation and Research, Arthritis Advisory Committee, March 4, Available from
Food and Drug Administration, Center for Drug Evaluation and Research, Arthritis Advisory Committee. Safety update meeting on TNF blocking agents. March 4, 2003. Available from: http://www.fda.gov/ohrms/dockets/ac/03/ transcripts/3930T1.htm/
Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis
Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 1991;325:467-72.
On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease
Kollias G, Douni E, Kassiotis G, Kontoyiannis D. On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol Rev 1999;169:175-94.
TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MR1 Analysis Group. Neurology 1999;53:457-65.
TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MR1 Analysis Group. Neurology 1999;53:457-65.
7
0029751983
Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2
van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996;47:1531-4.
Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides
Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9.
Association of rheumatoid arthritis with multiple sclerosis: Report of 14 cases and discussion of its significance [letter]
Toussirot E, Pertuiset E, Martin A, et al. Association of rheumatoid arthritis with multiple sclerosis: report of 14 cases and discussion of its significance [letter]. J Rheumatol 2006;33:1027-8.
